Status and phase
Conditions
Treatments
About
This is a Phase III, randomized, multicenter, 2-arm, open-label clinical trial designed to compare the safety and efficacy of Hemay022+Aromatase inhibitor(AI) with that of capecitabine + lapatinib in participants with ER+/HER2+ locally advanced or metastatic breast cancer. Participants will be treated until disease progression (PD), unmanageable toxicity, or study termination. Once disease progression is reported, all participants will be followed for survival every 3 months until death, loss to follow-up.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age ≥18 years old； Subjects must give informed consent to the study before the study entry and voluntarily sign a written informed consent form; Breast cancer subjects diagnosed by pathology; ER positive and HER2 over-expression; Advanced/metastatic breast cancer that has previously received treatment failure with trastuzumab (or trastuzumab biosimilar) regimen; Measurable and/or nonmeasurable disease; (Eastern Cooperative Oncology Group)ECOG Performance Status of 0-1; The estimated survival time is more than 3 months; Postmenopausal women; Adequate bone marrow, liver, kidney, and coagulation Bone Marrow Function; All previous treatment-related toxicities must be Common Terminology Criteria of Adverse Events (CTCAE ,version 5.0) ≤ Grade 2 at the time of randomization, except for hair loss, pigmentation, and long-term toxicity caused by radiotherapy (which cannot be recovered by the investigator's judgment)； Women patients of childbearing age (including their partners) have no pregnancy plan and voluntarily take effective contraceptive measures from the signing of the informed consent form to 3 months after the last medication.
Exclusion criteria
Patients with visceral crisis; Patients with the presence of spinal cord compression or brain, meningeal metastases; Patients who have been treated with a small molecule HER2 tyrosine kinase inhibitor (HER2-TKI) (medication course ≤2 weeks is excluded) Have received radiotherapy within 4 weeks prior to study； Have received chemotherapy for advanced breast cancer> 1 lines ; Patients with parenteral nutrition; malabsorption syndrome; or any condition possibly affecting drug absorption or inability to tolerate oral medications; Use of any drug that inhibits or induces hepatic metabolism of Hemay022 within 2 weeks prior to study and entire study duration; Patients who are known to have a history of allergies to Hemay022, lapatinib、AI (letrozole, exemestane) capecitabine or similar drugs; Left ventricular ejection fraction (LVEF) <50％; Positive blood for human immunodeficiency virus (HIV antibody); Positive hepatitis B surface antigen and HBV-DNA>upper limit of normal; Active hepatitis C virus (HCV) infection Patients with active infection requiring intravenous anti-infective treatment Arrhythmias requiring treatment ; Confirmed QTc prolongation (≥500ms) ; People with a history of interstitial lung disease that needs treatment, a history of radiation pneumonitis, or clinically active interstitial lung disease Have received other clinical trial drugs within 4 weeks before the study Major surgery or injury less than 4 weeks before the study The study period must be accompanied by other antitumor therapy，such as chemotherapy, targeted therapy, hormone therapy, immunotherapy, radiotherapy (except symptomatic local radiotherapy) Any other malignant cancer within 5 years with the exception of adequately treated cervical cancer in situ or basal and squamous cutaneous cell carcinomas Any condition that would make the subject inappropriate for this study by the investigator's judgment
Primary purpose
Allocation
Interventional model
Masking
339 participants in 2 patient groups
Loading...
Central trial contact
Huiping Li
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal